ASCO 2018 | Sacituzumab govitecan for treatment-refractory metastatic breast cancer

Aditya Bardia, MD, MPH, of Massachusetts General Hospital, Boston, MA, discusses the promising efficacy data of sacituzumab govitecan, an anti-Trop-2/SN-38 antibody-drug conjugate (ADC), for treatment-refractory HR+/HER2- metastatic breast cancer (NCT01631552). Prof. Bardia explains the next steps for the further development of this exciting agent, highlighting what indications this treatment is seeking approvals in. He also covers the potential of this ADC for early breast cancer and in combination with PARP inhibitors. This interview was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.